A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT02366143. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).
Study identification
- NCT ID
- NCT02366143
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,202 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Drug
- Bevacizumab Drug
- Carboplatin Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2015 (Actual)
- Primary completion
- Sep 13, 2019 (Actual)
- Completion
- Dec 7, 2020 (Actual)
- Last update posted
- Sep 23, 2021
2015 – 2020
United States locations
- U.S. sites
- 61
- U.S. states
- 27
- U.S. cities
- 58
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers | Chandler | Arizona | 85224 | — |
| Arizona Oncology Associates | Flagstaff | Arizona | 86001 | — |
| Southern CA Permanente Med Grp | Bellflower | California | — | — |
| Marin Cancer Care Inc | Greenbrae | California | 94904 | — |
| Scripps Health | La Jolla | California | 92037 | — |
| Chao Family Comprehensive Cancer Center UCI | Orange | California | 92868 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Kaiser Permanente | Lonetree | Colorado | 80124 | — |
| Danbury Hospital | Danbury | Connecticut | 06810 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Holy Cross Hospital Inc | Fort Lauderdale | Florida | 33308 | — |
| Cancer Specialists of North Florida - Baptist South | Jacksonville | Florida | 32258 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Piedmont Cancer Institute, PC | Atlanta | Georgia | 30318 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Univ of Chicago | Chicago | Illinois | 60637 | — |
| Ingalls Memorial Hospital | Harvey | Illinois | 60426 | — |
| Oncology Specialists, S.C. | Park Ridge | Illinois | 60068 | — |
| Hematology-Oncology; Associates of the Quad Cities | Bettendorf | Iowa | 52722 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| New England Cancer Specialists | Scarborough | Maine | 04074 | — |
| Mercy Medical Center | Baltimore | Maryland | 21202 | — |
| Regional Cancer Care Associates | Bethesda | Maryland | 20817 | — |
| Maryland Oncology Hematology, P.A. | Columbia | Maryland | 21044 | — |
| St. Joseph Mercy Health System | Ann Arbor | Michigan | 48106 | — |
| St. Luke's Regional Cancer Center | Duluth | Minnesota | 55805 | — |
| Park Nicolett - Frauenshuh Cancer Center | Saint Louis Park | Minnesota | 55426 | — |
| St. Luke's Cancer Institute | Kansas City | Missouri | 64111 | — |
| Missouri Baptist Medical Center | St Louis | Missouri | 63131 | — |
| Billings Clinic | Billings | Montana | 59102 | — |
| Montana Cancer Specialists | Missoula | Montana | 59802 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89014 | — |
| Summit Medical Group | Berkeley Heights | New Jersey | 07922 | — |
| Valley Hospital; Oncology Research | Paramus | New Jersey | 07652 | — |
| Regional Cancer Care Associates LLC | Sewell | New Jersey | 08080 | — |
| Maimonides Medical Center | Brooklyn | New York | 11219 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| First Health of the Carolinas | Pinehurst | North Carolina | 28374 | — |
| University of Cincinnati | Cincinnati | Ohio | 45203-0542 | — |
| Mercy St Anne Hospital | Toledo | Ohio | 43623 | — |
| Bend Memorial Clinic | Bend | Oregon | 97701 | — |
| St. Charles Medical Center Bend; Cancer Care Of The Cascades | Bend | Oregon | 97701 | — |
| Willamette Valley Cancer Insitute and Research Center | Springfield | Oregon | 97477 | — |
| St. Luke's Cancer Care Associates | Bethlehem | Pennsylvania | 18015 | — |
| Allegheny Cancer Center | Pittsburgh | Pennsylvania | 15212 | — |
| Univ of Pittsburgh Medical Ctr | Pittsburgh | Pennsylvania | 15232 | — |
| West Clinic | Germantown | Tennessee | 38138 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37920 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| Longview Cancer Center | Longview | Texas | 75601 | — |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23226 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| MultiCare Regional Cancer Center - Auburn | Auburn | Washington | 98002-4117 | — |
| Providence Regional Cancer Partnership | Everett | Washington | 98201 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Medical Oncology Associates | Spokane | Washington | 99208 | — |
| West Virginia University; Mary Babb Randolph Can Ctr | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 179 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02366143, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 23, 2021 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02366143 live on ClinicalTrials.gov.